North Ireland-based cancer diagnostics firm GenoMe Diagnostics raised GBP 1.4 million (USD 1.7 million) in private and public funding. Qubis, Co-Fund NI, and UK-based Deepbridge Capital participated in the funding round. 

The funds will be used to develop OvaMe, a blood test used to detect early-stage ovarian cancer, as well as to support regulatory filings in the UK, US, and the EU. The company also plans to hire additional laboratory scientists, as well as expand its sales and marketing teams.

The investment also included GBP 0.5 million (USD 0.6 million) from UK’s national innovation agency, Innovate. This grant will support a project that involves GenoMe Diagnostics and researchers from QUB. The aim of the project is to enhance GenoMe’s platform for the early detection of various types of cancer. 

GenoMe Diagnostics specializes in developing and providing diagnostic solutions for the early detection and monitoring of cancer. The company uses genomic technologies and bioinformatics to provide diagnostic tools that can improve patient outcomes. Spun out of Queen’s University Belfast, the company collaborates with researchers and clinicians from the university to advance their technology and research.